Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IPH-6101 by Innate Pharma for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
IPH-6101 by Innate Pharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
IPH-6101 by Innate Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
IPH-6101 by Innate Pharma for Myelodysplastic Syndrome: Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
IPH-6101 by Innate Pharma for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Monalizumab by Innate Pharma for Small-Cell Lung Cancer: Likelihood of Approval
Monalizumab is under clinical development by Innate Pharma and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
IPH-6501 by Innate Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
IPH-6501 by Innate Pharma for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...
IPH-6501 by Innate Pharma for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
IPH-6501 by Innate Pharma for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...
IPH-6501 by Innate Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
IPH-6501 by Innate Pharma for Mantle Cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
IPH-6501 by Innate Pharma for Follicular Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
IPH-6501 by Innate Pharma for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
IPH-6501 by Innate Pharma for Thymic Carcinoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase...
IPH-6501 by Innate Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...